查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1715347

重症加護治療市場按產品類型、給藥途徑、藥物類型、治療用途和最終用戶分類－2025-2030 年全球預測

Critical Care Therapeutics Market by Product Type, Administration Routes, Drug Types, Therapeutic Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 198 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

重症加護治療市場預計到 2024 年將達到 14 億美元，到 2025 年將達到 14.8 億美元，到 2030 年將達到 19.4 億美元，複合年成長率為 5.49%。

主要市場統計數據
基準年2024年 14億美元
預計2025年 14.8億美元
預測年份 2030 19.4億美元
複合年成長率（%） 5.49%

重症加護醫學是現代醫學中最具活力和變革性的領域之一，其特點是技術進步迅速、臨床實踐不斷發展。在當今快節奏的醫療保健環境中，快速決策和有針對性的干涉對於實現最佳患者治療效果至關重要。該領域見證了技術創新和嚴謹臨床研究的非凡融合，重新定義瞭如何在不同的醫療環境中提供重症加護。本報告首先提供了重症加護治療的全面框架，並強調了技術和臨床專業知識在管理危及生命的疾病中發揮的重要作用。

透過整合尖端技術和循證實踐，該行業不斷突破重症加護環境的極限。醫療設備、藥物和支持性護理的進步有可能挽救生命並降低發病率。隨著慢性病的增加和加護治療需求的增加，該領域的技術創新不僅提高了患者的存活率，而且還為優質照護設定了標準。對病患管理完美的不懈追求滿足了對強大即時資料的迫切需求，促進了世界各地加護病房的決策能力。

由於不斷發展的臨床挑戰需要緊急和關鍵的適應，本報告提供了一個策略觀點，說明相關人員如何重新構想治療、診斷和管理嚴重的方法。後續章節詳細介紹了格局的變革性變化，提供了跨多個參數的關鍵細分見解，並回顧了區域和公司趨勢。這項全面的調查旨在讓決策者獲得細緻的了解，從而應對不斷變化的重症加護治療領域。

改變重症加護藥物市場

近年來，重症加護醫學領域經歷了變革時期，反映了個人化和綜合護理的更廣泛趨勢。利用即時資料和預測分析的技術正在增強傳統的加護治療模式，幫助臨床醫生預測併發症並迅速介入。這一演變的一個關鍵驅動力是先進醫療設備和數位健康解決方案的整合，從而促進對患者健康參數的持續監測。這種整合促進了重症加護的更積極主動的方法，治療策略對患者快速變化的臨床狀況更具回應性。

多學科專業知識的融合進一步推動了重症加護的發展，臨床醫生、生物醫學工程師和資料科學家共同合作創造了創新的護理模式。這種協同效應正在重塑治療方案，並使得處理複雜的患者病例更加協調。高清影像、機器人輔助干預和智慧輸液系統只是重新定義加護治療環境中患者照護的部分技術進步。此外，採用微創技術和精準治療方法可以降低風險、縮短恢復時間並改善整體患者體驗。

治療格局的變化不僅限於技術，還涉及監管和報銷領域。政策變革和獎勵主導框架正在鼓勵醫療保健提供者投資先進的護理模式。此外，更重視以病人為中心的結果，確保創新與道德標準和臨床效果緊密結合。因此，行業領導者現在正在重新調整其策略目標，不僅要涵蓋技術優勢，還要涵蓋患者照護的全面改善。這些累積的進步奠定了重症加護新時代的基礎，該時代強調提供及時、有效和針對患者的治療性介入。

對市場動態的關鍵細分洞察

透過深入研究重症加護治療市場的多個方面的全面細分分析，我們可以對重症監護治療市場有更細緻的了解。根據產品類型進行細分可區分各種組件，例如植入式設備、輸液袋、藥物、監測設備、注射器和導管以及人工呼吸器。在這個基於產品的細分中，藥物被細分為抗生素、神經肌肉阻斷劑、鎮靜劑、溶栓劑等類別，突顯了藥物治療的複雜性和專業化。

除了以產品為導向的分析外，市場還根據給藥途徑進行細分，治療藥物分為吸入、靜脈和口服途徑。每種途徑都有其自身的優勢和挑戰，其選擇受患者病情和急性護理要求的影響。細分進一步分為藥物類型，區分止痛藥、抗菌藥和鎮靜劑。深入分析，止痛藥分為非鴉片類鎮痛藥和鴉片類鎮痛藥，抗菌藥物分為抗生素和抗病毒藥物，抗生素本身又分為頻譜和窄頻譜。鎮靜劑被仔細細分為苯二氮平類鎮靜劑和非苯二氮平類鎮靜劑，並對每一類的功效和安全性進行評估。

同樣重要的是基於治療應用的細分，涵蓋心血管護理、緊急復甦、神經病變、腎臟替代療法、呼吸護理等治療頻譜。後兩個領域進一步細分為神經系統疾病（透過顱內壓監測和創傷性腦損傷進行評估）和呼吸照護（細分為氣喘、慢性阻塞性肺病和肺水腫的管理）。最後，按最終用戶細分描述了這些產品和治療方法在不同環境中的應用，例如門診手術中心、家庭醫療保健、醫院和長期護理機構。這些全面的細分洞察不僅增強了治療和服務的針對性，而且還推動了客製化策略以滿足不同患者群體的特定需求。

目錄

第1章 引言

第2章調查方法

第3章執行摘要

第4章 市場概述

第5章 市場洞察

  • 市場動態
    • 驅動程式
      • 隨著人口老化，加護治療和嚴重疾病的需求日益增加。
      • 提高對需要緊急治療性介入的急性疾病的認知和診斷
    • 限制因素
      • 高昂的研發成本是重症加護醫學發展的一大障礙。
    • 機會
      • 針對非侵入性嚴重監護監測技術的研究進行投資
      • 在嚴重監護環境中使用人工智慧和機器學習進行預測診斷
    • 任務
      • 對重症加護治療領域激烈競爭和市場分化的管理擔憂
  • 市場區隔分析
    • 產品類型：提高重症加護藥物的製藥偏好
    • 最終用戶：擴大醫院重症加護藥物的使用
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社會
    • 技術的
    • 合法的
    • 環境

第6章重症加護治療市場（依產品類型）

  • 嵌入式裝置
  • 靜脈輸液袋
  • 製藥
    • 抗生素
    • 神經肌肉阻斷劑
    • 鎮靜劑
    • 纖溶藥物
  • 監控設備
  • 注射器和導管
  • 人工呼吸器

第7章重症加護治療市場（依給藥途徑）

  • 吸入
  • 靜脈
  • 口服

第8章重症加護治療市場（依藥物類型）

  • 止痛藥
    • 非鴉片類止痛藥
    • 鴉片類止痛藥
  • 抗菌劑
    • 抗生素
      • 頻譜抗生素
      • 窄效抗生素
    • 抗病毒藥物
  • 鎮靜劑
    • 苯二氮平類藥物
    • 非苯二氮平類鎮靜劑

第9章重症加護治療市場（依治療應用）

  • 心血管護理
  • 緊急復甦
  • 神經系統疾病
    • 顱內壓監測
    • 創傷性腦損傷
  • 腎臟替代療法
  • 呼吸護理
    • 氣喘
    • 慢性阻塞性肺病
    • 肺水腫

第 10 章重症加護治療市場（按最終用戶）

  • 門診手術中心
  • 家庭醫療保健
  • 醫院
  • 長期照護機構

11.美洲重症加護藥物市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

12. 亞太重症加護藥物市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

13. 歐洲、中東和非洲重症加護藥物市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第14章競爭格局

  • 2024年市場佔有率分析
  • 2024年FPNV定位矩陣
  • 競爭情境分析
  • 戰略分析與建議

公司名單

  • Abeona Therapeutics Inc.
  • ADMA Biologics, Inc.
  • Albumedix Ltd. by Sartorius AG
  • Asklepios BioPharmaceutical, Inc.
  • Aspen Group
  • Bio Products Laboratory Ltd.
  • BioDelivery Sciences International, Inc.
  • Biotest AG
  • CSL Limited
  • Grifols SA
  • Kedrion Spa
  • Novartis AG
  • Octapharma AG
  • Shanghai RAAS
  • Takeda Pharmaceutical Co. Ltd.
Product Code: MRR-4311CE1A33EE

The Critical Care Therapeutics Market was valued at USD 1.40 billion in 2024 and is projected to grow to USD 1.48 billion in 2025, with a CAGR of 5.49%, reaching USD 1.94 billion by 2030.

KEY MARKET STATISTICS
Base Year [2024] USD 1.40 billion
Estimated Year [2025] USD 1.48 billion
Forecast Year [2030] USD 1.94 billion
CAGR (%) 5.49%

Critical care therapeutics represents one of the most dynamic and transformative sectors in modern medicine, characterized by rapid technological advancements and evolving clinical practices. In today's fast-paced healthcare environment, rapid decisions and precise interventions are essential to achieve optimal patient outcomes. The field has witnessed an extraordinary confluence of innovation and rigorous clinical research that has redefined how critical care is delivered across diverse healthcare settings. This report starts by elucidating the overarching framework of critical care therapeutics, highlighting the integral role of technology and clinical expertise in managing life-threatening conditions.

By integrating state-of-the-art methods and evidence-based practices, the industry continues to push the boundaries of what is possible in critical care environments. Advancements in medical devices, drug therapies, and supportive care are expanding the potential to save lives and reduce morbidity. With the increasing prevalence of chronic diseases and the subsequent higher demand for intensive care, innovations in this space are not only improving patient survival rates but are also creating a benchmark for quality care. The relentless pursuit of perfection in patient management complements the critical need for robust, real-time data, fostering enhanced decision-making in intensive care units around the globe.

As evolving clinical challenges demand immediate and significant adaptation, this report provides a strategic view on how stakeholders are reshaping their approaches to therapy, diagnosis, and management of critical conditions. The subsequent sections will detail the transformative shifts in the landscape, offer key segmentation insights across multiple parameters, and review regional as well as company-specific trends. This comprehensive examination aims to equip decision-makers with the nuanced understanding needed to navigate the ever-changing realm of critical care therapeutics.

Transformative Shifts in the Critical Care Landscape

In recent years, the landscape of critical care therapeutics has undergone transformative shifts that reflect a broader trend towards personalized medicine and integrated care. The traditional model of intensive care has been augmented with technologies that leverage real-time data and predictive analytics, enabling clinicians to anticipate complications and intervene promptly. A major driver behind this evolution is the integration of advanced medical devices and digital health solutions that facilitate the continuous monitoring of patient health parameters. This integration has fostered a more proactive approach to critical care, where therapeutic strategies are now more sensitive to the rapidly changing clinical status of patients.

The evolution in critical care is further bolstered by the convergence of interdisciplinary expertise, where collaborations between clinicians, biomedical engineers, and data scientists result in innovative care models. This synergy is reshaping treatment protocols and enabling a more coordinated approach to managing complex patient cases. High-definition imaging, robotic-assisted interventions, and smart infusion systems represent just a few of the technological advances that have redefined patient care in intensive settings. Moreover, the adoption of minimally invasive techniques and precision therapeutics mitigates risks, reduces recovery times, and enhances overall patient experience.

The shifts in the therapeutic landscape are not solely confined to technology but extend into the regulatory and reimbursement territories as well. Policy changes and incentive-driven frameworks are encouraging healthcare providers to invest in advanced care models. Furthermore, the growing emphasis on patient-centric outcomes is ensuring that innovations are closely aligned with ethical standards and clinical effectiveness. As a result, industry leaders are now recalibrating their strategic goals to encompass not only technological superiority but also the holistic improvement of patient care. These collective advancements underscore a new era in critical care, where the focus is on delivering timely, efficient, and tailored therapeutic interventions.

Key Segmentation Insights in Market Dynamics

A nuanced understanding of the critical care therapeutics market is achieved through comprehensive segmentation analysis that delves into multiple dimensions of the industry. The segmentation based on product type distinguishes various components such as implantable devices, intravenous infusion bags, medications, monitoring devices, syringes and catheters, and ventilators. Within this product-based segmentation, medications receive further in-depth scrutiny by segmenting them into categories including antibiotics, neuromuscular blockers, sedatives, and thrombolytics, which underscores the complexity and specialization present within drug therapeutics.

In addition to product-oriented analysis, the market is also segmented by administration routes that categorize therapies into inhalation, intravenous, and oral pathways. Each route possesses unique merits and challenges, with choices influenced by patient conditions and acute care requirements. The segmentation further extends to drug types where distinctions are made among analgesics, antimicrobials, and sedatives. Diving deeper, analgesics are analyzed as non-opioid analgesics and opioid analgesics; likewise, antimicrobials are divided into antibiotics and antivirals, with antibiotics themselves further differentiated into broad-spectrum and narrow-spectrum types. Sedatives are carefully examined by their subclassifications into benzodiazepines and non-benzodiazepine sedatives, ensuring that each category is evaluated for both efficacy and safety.

Equally important is the segmentation based on therapeutic application which covers a spectrum of care such as cardiovascular treatment, emergency resuscitation, neurological disorders, renal replacement therapy, and respiratory care. The latter two areas receive additional granularity with neurological disorders being evaluated through intracranial pressure monitoring and traumatic brain injury, and respiratory care dissected into the management of asthma, chronic obstructive pulmonary disease, and pulmonary edema. Lastly, segmentation by end-user illustrates the application of these products and therapies in distinct settings including ambulatory surgical centers, home healthcare, hospitals, and long-term care facilities. These comprehensive segmentation insights not only enable enhanced targeting of therapies and services but also drive customized strategies to meet the specific needs of diverse patient populations.

Based on Product Type, market is studied across Implantable Devices, Intravenous Infusion Bags, Medications, Monitoring Devices, Syringes & Catheters, and Ventilators. The Medications is further studied across Antibiotics, Neuromuscular Blockers, Sedatives, and Thrombolytics.

Based on Administration Routes, market is studied across Inhalation, Intravenous, and Oral.

Based on Drug Types, market is studied across Analgesics, Antimicrobials, and Sedatives. The Analgesics is further studied across Non-Opioid Analgesics and Opioid Analgesics. The Antimicrobials is further studied across Antibiotics and Antivirals. The Antibiotics is further studied across Broad-Spectrum Antibiotics and Narrow-Spectrum Antibiotics. The Sedatives is further studied across Benzodiazepines and Non-Benzodiazepine Sedatives.

Based on Therapeutic Application, market is studied across Cardiovascular Care, Emergency Resuscitation, Neurological Disorders, Renal Replacement Therapy, and Respiratory Care. The Neurological Disorders is further studied across Intracranial Pressure Monitoring and Traumatic Brain Injury. The Respiratory Care is further studied across Asthma, Chronic Obstructive Pulmonary Disease, and Pulmonary Edema.

Based on End-User, market is studied across Ambulatory Surgical Centers, Home Healthcare, Hospitals, and Long-Term Care Facilities.

Key Regional Insights Across Global Markets

From a regional perspective, the landscape of critical care therapeutics reflects a diverse and rapidly evolving global tableau. Analysis of the Americas reveals a strong emphasis on advanced healthcare infrastructure and high investment in critical care innovation, which drives significant strides in patient management and therapeutic care. In contrast, regions classified as Europe, Middle East & Africa depict a spectrum of developments ranging from well-established healthcare systems with advanced technological adoption to emerging markets where growth is being spurred by recent investments and regulatory reforms. These regions are quickly catching up by integrating modern therapeutic solutions that enhance clinical outcomes.

Turning to the Asia-Pacific, the story is one of rapid expansion and dynamic transformation. This region is characterized by its swift adoption of novel technologies and an impressive proliferation of research and development activities. Health systems in Asia-Pacific benefit from a blend of traditional practices and contemporary innovations, resulting in tailored solutions that address both chronic and acute care challenges. The disparities in regional wealth and infrastructural capabilities lead to distinct strategic approaches in market penetration, with localized solutions often emerging to bridge gaps and ensure the widespread availability of critical care services. Overall, the regional insights demonstrate that while each geographic area has its own distinctive challenges and opportunities, all are united by the common goal of elevating critical care delivery through innovative therapeutic strategies.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

Key Companies Driving Innovation and Growth

A host of leading companies are at the forefront of transforming the critical care therapeutics landscape. Organizations such as Abeona Therapeutics Inc., ADMA Biologics, Inc., and Albumedix Ltd. by Sartorius AG are spearheading novel research initiatives and clinical applications. Equally, leaders like Asklepios BioPharmaceutical, Inc., Aspen Group, and Bio Products Laboratory Ltd. bring extensive expertise in product innovation and market expansion. Companies such as BioDelivery Sciences International, Inc., Biotest AG, and CSL Limited are providing robust frameworks for therapeutic development, further enhancing the effectiveness of complex care systems. Moreover, Grifols SA, Kedrion Spa, Novartis AG, Octapharma AG, Shanghai RAAS, and Takeda Pharmaceutical Co. Ltd. represent industry powerhouses that continue to push the envelope in terms of research excellence, rigorous quality control, and heightened patient care. The strategic collaborations and continuous investment in research and development by these companies are critical drivers in the evolution of critical care therapeutics, ensuring that the most advanced treatments and technologies consistently reach the clinical forefront.

The report delves into recent significant developments in the Critical Care Therapeutics Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., ADMA Biologics, Inc., Albumedix Ltd. by Sartorius AG, Asklepios BioPharmaceutical, Inc., Aspen Group, Bio Products Laboratory Ltd., BioDelivery Sciences International, Inc., Biotest AG, CSL Limited, Grifols SA, Kedrion Spa, Novartis AG, Octapharma AG, Shanghai RAAS, and Takeda Pharmaceutical Co. Ltd.. Actionable Recommendations for Market Leaders

In light of the comprehensive analysis, several actionable recommendations emerge for leaders within the critical care therapeutics industry. First, it is imperative to enhance investment in digital health and data analytics technologies that facilitate real-time decision-making in clinical settings. By leveraging predictive analytics, companies can optimize treatment protocols and improve patient outcomes. Second, fostering strategic partnerships will be critical; collaborations between device manufacturers, pharmaceutical companies, and clinical research organizations can accelerate innovation and streamline regulatory compliance.

Leaders should also consider diversifying their portfolio offerings by expanding into underpenetrated segments such as niche drug formulations and targeted therapy applications. This strategic diversification will not only mitigate risks associated with market fluctuations but also tap into unmet clinical needs. Furthermore, expanding market presence through regional diversifications, especially in emerging markets, promises untapped growth potential. Integrating localized strategies that take into account regional healthcare dynamics and regulatory environments will empower companies to tailor their product offerings more effectively.

Lastly, continuous investment in cutting-edge R&D is essential. By prioritizing the development of next-generation therapies and advanced medical devices, industry players can maintain competitive advantage and meet the evolving expectations of healthcare providers. Leaders should emphasize sustainable growth by balancing immediate market opportunities with long-term innovation strategies, ensuring that their organizations remain resilient and well-positioned in a rapidly evolving global landscape.

Conclusion and Future Outlook

The analysis presented in this report underscores a period of significant transformation in the landscape of critical care therapeutics. Technological innovations, combined with evolving regulatory frameworks and a renewed focus on patient outcomes, are collectively reshaping the future of intensive care. The multi-faceted segmentation insights and regional trends illustrate that the industry is on the cusp of embracing more personalized and efficient care models, driven by data analytics and collaborative technologies.

As the market continues to mature, stakeholders must remain cognizant of the dynamic interplay between technological advancements and the evolving clinical demands. With challenges such as rising healthcare costs and the burden of chronic diseases, the importance of precision and efficacy in critical care treatments cannot be overstated. Looking ahead, companies that embrace agility, nurture innovation, and adopt patient-centric approaches will be best positioned to capitalize on emerging opportunities. The future of critical care therapeutics is one that promises improved survival rates and enhanced quality of care, ultimately translating to better patient outcomes across all healthcare settings.

In summary, the insights derived from this comprehensive review serve as a roadmap for industry leaders aiming to secure long-term success. By aligning strategic initiatives with evolving market trends and maintaining a consistent focus on innovation, stakeholders can drive meaningful improvements in critical care delivery while simultaneously building a robust and sustainable business model.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising geriatric population contributing to higher demand for intensive and critical care services
      • 5.1.1.2. Growing awareness and diagnosis rates of acute medical conditions requiring urgent care interventions
    • 5.1.2. Restraints
      • 5.1.2.1. High research and development costs are a significant barrier in critical care therapeutics
    • 5.1.3. Opportunities
      • 5.1.3.1. Targeting investment in research for non-invasive critical care monitoring technologies
      • 5.1.3.2. Leveraging AI and machine learning for predictive diagnostics in critical care settings
    • 5.1.4. Challenges
      • 5.1.4.1. Concern associated with managing high competition and market fragmentation in the critical care therapeutics sector
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product Type: Increasing preference for medications in critical care therapeutics
    • 5.2.2. End-User: Expanding utilization of critical care therapeutics in hospitals
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Critical Care Therapeutics Market, by Product Type

  • 6.1. Introduction
  • 6.2. Implantable Devices
  • 6.3. Intravenous Infusion Bags
  • 6.4. Medications
    • 6.4.1. Antibiotics
    • 6.4.2. Neuromuscular Blockers
    • 6.4.3. Sedatives
    • 6.4.4. Thrombolytics
  • 6.5. Monitoring Devices
  • 6.6. Syringes & Catheters
  • 6.7. Ventilators

7. Critical Care Therapeutics Market, by Administration Routes

  • 7.1. Introduction
  • 7.2. Inhalation
  • 7.3. Intravenous
  • 7.4. Oral

8. Critical Care Therapeutics Market, by Drug Types

  • 8.1. Introduction
  • 8.2. Analgesics
    • 8.2.1. Non-Opioid Analgesics
    • 8.2.2. Opioid Analgesics
  • 8.3. Antimicrobials
    • 8.3.1. Antibiotics
      • 8.3.1.1. Broad-Spectrum Antibiotics
      • 8.3.1.2. Narrow-Spectrum Antibiotics
    • 8.3.2. Antivirals
  • 8.4. Sedatives
    • 8.4.1. Benzodiazepines
    • 8.4.2. Non-Benzodiazepine Sedatives

9. Critical Care Therapeutics Market, by Therapeutic Application

  • 9.1. Introduction
  • 9.2. Cardiovascular Care
  • 9.3. Emergency Resuscitation
  • 9.4. Neurological Disorders
    • 9.4.1. Intracranial Pressure Monitoring
    • 9.4.2. Traumatic Brain Injury
  • 9.5. Renal Replacement Therapy
  • 9.6. Respiratory Care
    • 9.6.1. Asthma
    • 9.6.2. Chronic Obstructive Pulmonary Disease
    • 9.6.3. Pulmonary Edema

10. Critical Care Therapeutics Market, by End-User

  • 10.1. Introduction
  • 10.2. Ambulatory Surgical Centers
  • 10.3. Home Healthcare
  • 10.4. Hospitals
  • 10.5. Long-Term Care Facilities

11. Americas Critical Care Therapeutics Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Critical Care Therapeutics Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Critical Care Therapeutics Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2024
  • 14.2. FPNV Positioning Matrix, 2024
  • 14.3. Competitive Scenario Analysis
    • 14.3.1. Mankind Pharma's transformative acquisition of Bharat Serums
    • 14.3.2. Poly Medicure targets international expansion in critical care with significant investment and strategic acquisitions
    • 14.3.3. BD enhances smart connected care through strategic acquisition of Edwards Lifesciences' critical care unit
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abeona Therapeutics Inc.
  • 2. ADMA Biologics, Inc.
  • 3. Albumedix Ltd. by Sartorius AG
  • 4. Asklepios BioPharmaceutical, Inc.
  • 5. Aspen Group
  • 6. Bio Products Laboratory Ltd.
  • 7. BioDelivery Sciences International, Inc.
  • 8. Biotest AG
  • 9. CSL Limited
  • 10. Grifols SA
  • 11. Kedrion Spa
  • 12. Novartis AG
  • 13. Octapharma AG
  • 14. Shanghai RAAS
  • 15. Takeda Pharmaceutical Co. Ltd.

LIST OF FIGURES

  • FIGURE 1. CRITICAL CARE THERAPEUTICS MARKET MULTI-CURRENCY
  • FIGURE 2. CRITICAL CARE THERAPEUTICS MARKET MULTI-LANGUAGE
  • FIGURE 3. CRITICAL CARE THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 4. CRITICAL CARE THERAPEUTICS MARKET SIZE, 2024 VS 2030
  • FIGURE 5. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 6. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 7. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2030 (%)
  • FIGURE 9. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2024 VS 2030 (%)
  • FIGURE 11. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2024 VS 2030 (%)
  • FIGURE 13. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2030 (%)
  • FIGURE 15. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2030 (%)
  • FIGURE 17. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 19. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2030 (%)
  • FIGURE 21. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
  • FIGURE 26. CRITICAL CARE THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 27. CRITICAL CARE THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CRITICAL CARE THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CRITICAL CARE THERAPEUTICS MARKET DYNAMICS
  • TABLE 7. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY IMPLANTABLE DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS INFUSION BAGS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROMUSCULAR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THROMBOLYTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MONITORING DEVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SYRINGES & CATHETERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY VENTILATORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INHALATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NON-OPIOID ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY OPIOID ANALGESICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY BROAD-SPECTRUM ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NARROW-SPECTRUM ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIVIRALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY BENZODIAZEPINES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NON-BENZODIAZEPINE SEDATIVES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY EMERGENCY RESUSCITATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY INTRACRANIAL PRESSURE MONITORING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY TRAUMATIC BRAIN INJURY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 45. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 46. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RENAL REPLACEMENT THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 47. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 48. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ASTHMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 49. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY CHRONIC OBSTRUCTIVE PULMONARY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 50. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PULMONARY EDEMA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 51. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 52. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 54. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY HOME HEALTHCARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 55. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 56. GLOBAL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY LONG-TERM CARE FACILITIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 57. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 59. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 60. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 61. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 62. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 63. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 64. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 65. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 66. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 67. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 68. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. AMERICAS CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 70. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 71. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 72. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 73. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 74. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 75. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 76. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 77. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 78. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 79. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 80. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 81. ARGENTINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 82. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 84. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 85. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 86. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 87. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 88. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 89. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 90. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 91. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 92. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 93. BRAZIL CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 94. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 95. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 96. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 97. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 98. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 99. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 100. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 101. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 102. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 103. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 104. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 105. CANADA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 106. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 107. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 108. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 109. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 110. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 111. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 112. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 113. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 114. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 115. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 116. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 117. MEXICO CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 119. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 120. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 121. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 122. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 123. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 124. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 125. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 126. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 127. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 128. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 129. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. UNITED STATES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 131. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 133. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 134. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 144. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 145. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 146. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 147. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 148. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 150. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 152. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 154. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 156. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 157. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 158. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 159. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 160. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 161. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 162. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 163. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 164. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 166. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 167. CHINA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 168. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 170. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 171. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 172. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 173. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 174. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 175. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 176. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 178. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 179. INDIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 182. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 183. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 184. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 185. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 186. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 187. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 188. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 190. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 191. INDONESIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 194. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 195. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 196. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 197. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 198. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 199. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 200. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 201. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 202. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 203. JAPAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 206. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 207. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 208. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 209. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 210. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 211. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 212. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 213. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 214. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 215. MALAYSIA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 218. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 219. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 220. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 222. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 224. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 225. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 226. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 227. PHILIPPINES CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 230. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 231. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 232. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 233. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 234. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 235. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 236. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 237. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 238. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 239. SINGAPORE CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 240. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 248. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 249. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 250. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 251. SOUTH KOREA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 252. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 254. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 255. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 256. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 257. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 258. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 259. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 260. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 261. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 262. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 263. TAIWAN CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 264. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 266. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 267. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 268. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 269. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 270. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 271. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 272. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 273. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 274. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 275. THAILAND CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 276. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 278. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 279. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 280. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 281. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 282. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 283. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 284. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 285. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 286. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 287. VIETNAM CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 288. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 290. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 291. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 292. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA CRITICAL CARE THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 301. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 302. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 303. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ADMINISTRATION ROUTES, 2018-2030 (USD MILLION)
  • TABLE 304. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY DRUG TYPES, 2018-2030 (USD MILLION)
  • TABLE 305. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANALGESICS, 2018-2030 (USD MILLION)
  • TABLE 306. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIMICROBIALS, 2018-2030 (USD MILLION)
  • TABLE 307. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY ANTIBIOTICS, 2018-2030 (USD MILLION)
  • TABLE 308. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY SEDATIVES, 2018-2030 (USD MILLION)
  • TABLE 309. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY THERAPEUTIC APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 310. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, 2018-2030 (USD MILLION)
  • TABLE 311. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY RESPIRATORY CARE, 2018-2030 (USD MILLION)
  • TABLE 312. DENMARK CRITICAL CARE THERAPEUTICS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 313. EGYPT CRITICAL CARE THERAPEUTICS MARKET SIZE, BY PRODUCT TYPE, 2018-2030 (USD MILLION)
  • TABLE 314. EGYPT CRITICAL CARE THERAPEUTICS MARKET SIZE, BY MEDICATIONS, 2018-2030 (USD MILLION)
  • TABLE 315. EGYPT CRITICAL CARE THERAPEUTICS